RCUS - Arcus Biosciences Inc
Close
17.12
-0.210 -1.227%
Share volume: 436,621
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$17.33
-0.21
-1.21%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-03 | 2022-11-02 | 2023-02-28 | 2023-05-09 | 2023-08-07 | 2023-11-07 | 2024-02-21 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 1.477 B | 1.394 B | 1.345 B | 1.254 B | 1.220 B | 1.191 B | 1.095 B | 1.293 B | |
| Current Assets | 1.227 B | 1.101 B | 1.067 B | 1.015 B | 986.000 M | 882.000 M | 831.000 M | 1.064 B | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 15.672 M | 21.625 M | 19.000 M | 25.000 M | 22.000 M | 27.000 M | 34.000 M | 29.000 M | |
| Short Term Investments | 15.672 M | 21.625 M | 19.000 M | 25.000 M | 22.000 M | 27.000 M | 34.000 M | 29.000 M | |
| Total Receivables | 39.027 M | 30.709 M | 39.000 M | 36.000 M | 34.000 M | 56.000 M | 38.000 M | 40.000 M | |
| Current Cash | 1.173 B | 1.049 B | 1.009 B | 954.000 M | 930.000 M | 799.000 M | 759.000 M | 995.000 M | |
| Total Non-current Assets | 249.298 M | 292.706 M | 278.000 M | 239.000 M | 234.000 M | 309.000 M | 264.000 M | 229.000 M | |
| Property Plant Equipment | 33.416 M | 33.892 M | 35.000 M | 37.000 M | 45.000 M | 50.000 M | 51.000 M | 51.000 M | |
| Other Assets | 10.523 M | 10.598 M | 114.000 M | 112.000 M | 109.000 M | 108.000 M | 106.000 M | 78.000 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.477 B | 1.394 B | 1.345 B | 1.254 B | 1.220 B | 1.191 B | 1.095 B | 1.293 B | |
| Total liabilities | 729.387 M | 695.121 M | 688.000 M | 654.000 M | 654.000 M | 671.000 M | 633.000 M | 586.000 M | |
| Total current liabilities | 164.024 M | 177.176 M | 193.000 M | 179.000 M | 180.000 M | 200.000 M | 184.000 M | 204.000 M | |
| Accounts Payable | 21.984 M | 10.546 M | 20.000 M | 28.000 M | 12.000 M | 17.000 M | 17.000 M | 16.000 M | |
| Other liabilities | 444.020 M | 398.750 M | 495.000 M | 475.000 M | 474.000 M | 471.000 M | 449.000 M | 382.000 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 444.020 M | 398.750 M | 495.000 M | 475.000 M | 474.000 M | 471.000 M | 449.000 M | 382.000 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 747.386 M | 698.701 M | 657.000 M | 600.000 M | 566.000 M | 520.000 M | 462.000 M | 707.000 M | |
| Common stock | 71.814 M | 72.236 M | 72.755 M | 73.000 M | 73.200 M | 74.600 M | 75.200 M | 86.200 M | |
| Retained earnings | -409.979 M | -474.898 M | -542.000 M | -622.000 M | -697.000 M | -768.000 M | -849.000 M | -853.000 M |